BioNTech SE (BNTX), Friday reached two separate settlements with the U.S. National Institutes of Health, and the University of Pennsylvania regarding the royalties payment of COVID-19 vaccine.
The Germany-based company has agreed to pay $791.5 million to the U.S. agency, whereas it would pay $467 million to UPenn to dismiss the lawsuit.
Moreover, BioNTech's partner Pfizer (PFE) for its COVID-19 vaccine has agreed to reimburse the company for up to $170 million of the claimed royalties payable to Penn for 2020-2023 sales in connection with the proposed Settlement Agreement.
Concurrently, the company has amended its license agreements to provide for a low single-digit percentage royalty on Net Sales of Licensed Products for 2024 onwards.
Currently, BioNTech's stock is trading at $114.25, up 0.42 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.